- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 8 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.9: 3 residues within 4Å:- Chain A: E.281, N.282
- Chain C: K.558
Ligand excluded by PLIPNAG.10: 3 residues within 4Å:- Chain A: N.331, P.579, Q.580
Ligand excluded by PLIPNAG.11: 1 residues within 4Å:- Chain A: N.603
Ligand excluded by PLIPNAG.12: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.13: 2 residues within 4Å:- Chain A: N.709, G.1131
Ligand excluded by PLIPNAG.14: 2 residues within 4Å:- Chain A: N.717, Q.1071
Ligand excluded by PLIPNAG.15: 3 residues within 4Å:- Chain A: A.706, N.1074
- Chain B: Q.895
Ligand excluded by PLIPNAG.16: 3 residues within 4Å:- Chain A: N.1098, G.1099, F.1103
Ligand excluded by PLIPNAG.17: 1 residues within 4Å:- Chain A: N.1134
Ligand excluded by PLIPNAG.18: 4 residues within 4Å:- Chain A: N.148, N.149, S.151, M.153
Ligand excluded by PLIPNAG.19: 3 residues within 4Å:- Chain A: N.616, T.618, E.619
Ligand excluded by PLIPNAG.20: 2 residues within 4Å:- Chain A: N.164, N.165
Ligand excluded by PLIPNAG.21: 3 residues within 4Å:- Chain A: F.338, G.339, N.343
Ligand excluded by PLIPNAG.22: 3 residues within 4Å:- Chain A: N.801, S.803, Q.804
Ligand excluded by PLIPNAG.23: 2 residues within 4Å:- Chain B: E.281, N.282
Ligand excluded by PLIPNAG.24: 2 residues within 4Å:- Chain B: N.616, T.618
Ligand excluded by PLIPNAG.25: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.26: 4 residues within 4Å:- Chain B: N.717, L.922, Q.926, Q.1071
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain B: N.1074, T.1076
Ligand excluded by PLIPNAG.28: 4 residues within 4Å:- Chain B: N.1098, T.1100, H.1101, F.1103
Ligand excluded by PLIPNAG.29: 1 residues within 4Å:- Chain B: N.1134
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain B: Y.28, N.61
Ligand excluded by PLIPNAG.31: 5 residues within 4Å:- Chain B: H.146, N.148, N.149, S.151, M.153
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain B: N.709, G.1131
- Chain C: D.796
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain B: N.234
Ligand excluded by PLIPNAG.34: 3 residues within 4Å:- Chain B: E.132, N.164, N.165
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain B: N.603, T.604
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain B: N.331, P.579, Q.580
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain B: N.801, S.803
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain C: E.281, N.282
Ligand excluded by PLIPNAG.39: 1 residues within 4Å:- Chain C: N.603
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain C: N.616, T.618
Ligand excluded by PLIPNAG.41: 2 residues within 4Å:- Chain C: H.655, N.657
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain C: N.709, N.710, G.1131
Ligand excluded by PLIPNAG.43: 3 residues within 4Å:- Chain C: N.717, Q.926, Q.1071
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain C: A.706, E.1072, N.1074
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain C: N.1098, T.1100, H.1101, F.1103
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain C: N.1134
Ligand excluded by PLIPNAG.47: 5 residues within 4Å:- Chain C: H.146, N.148, N.149, S.151, M.153
Ligand excluded by PLIPNAG.48: 1 residues within 4Å:- Chain C: N.331
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain C: F.338, G.339, N.343
Ligand excluded by PLIPNAG.50: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain C: N.165
Ligand excluded by PLIPNAG.52: 3 residues within 4Å:- Chain C: G.232, I.233, N.234
Ligand excluded by PLIPNAG.53: 3 residues within 4Å:- Chain C: N.801, S.803, Q.804
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Custodio, T.F. et al., Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat Commun (2020)
- Release Date
- 2020-10-21
- Peptides
- Spike glycoprotein: ABC
Neutralising sybody (Sb23): DEF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
F
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-mer
- Ligands
- 8 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 45 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Custodio, T.F. et al., Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat Commun (2020)
- Release Date
- 2020-10-21
- Peptides
- Spike glycoprotein: ABC
Neutralising sybody (Sb23): DEF - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
F